在卵巢癌细胞中,与帕克利塔塞尔耐药性相关的代谢事件
Filipa Amaro1,2, Mariana Nunes3,4, Paula Guedes de Pinho1,2
1Associate Laboratory i4HB - Institute for Health and Bioeconomy, University of Porto, 4050-313, Porto, Portugal.
Metabolomics : Official journal of the Metabolomic Society
|October 16, 2025
概括
在卵巢癌 (OC) 中对帕克利塔塞尔 (PTX) 耐药性的了解很少. 代谢学揭示了像谷氨代谢这样的改变途径,这表明了提高化疗疗效率的目标.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 化学疗法耐药性 抗化学疗法耐药性
背景情况:
- 标准的卵巢癌 (OC) 治疗包括手术和 - 纳化疗.
- 帕克利塔塞尔 (PTX) 耐药性是OC复发和治疗失败的主要原因.
- 在OC中对PTX耐药性的代谢机制尚不清楚.
研究的目的:
- 系统地描述与OC中PTX耐药性相关的代谢重编程.
- 识别潜在的治疗漏洞,以克服PTX耐药性.
- 为了提高白金 - 纳化疗在先进的OC中的疗效.
主要方法:
- 采用了获得PTX耐药性 (OVCAR8 PTX) 和其父母对应物 (OVCAR8 PAR) 的异构体体外模型.
- 应用非向代谢学,使用气色谱-质谱法 (GC-MS) 进行细胞内和细胞外代谢物分析.
- 进行多变量和单变量统计分析以确定显著的代谢差异.
主要成果:
- 在抗PTX的OC细胞中发现了一种独特的代谢特征.
- 观察到显著升高的甘氨酸,myo-inositol,pyroglutamate,proline和 taurine 的水平.
- 检测到降低了甘油,葡萄糖和谷氨酸的水平,表明改变了氧化还原,能量,氨基酸和透应激通路.
结论:
- 已识别的代谢特征表明失调的途径,包括谷氨和牛代谢,作为潜在的治疗点.
- 对这些途径的药理向可以逆转PTX耐药性并恢复化学敏感性.
- 这提供了一个合理的策略,以改善在先进的OC中白金-纳治疗的结果.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K